In prostate cancer, loss of the tumor suppressor PTEN increases ERG levels by inhibiting PTEN-mediated degradation of ERG [97,98] and resulting in a cascade of events that induce cell proliferation through the Hippo pathway. Here, ERG is linked to prostate cancer.